Home Insight into novel therapeutic targets in heart failure: a comprehensive review
Article
Licensed
Unlicensed Requires Authentication

Insight into novel therapeutic targets in heart failure: a comprehensive review

  • Dalia O. Saleh and Ahmed A. Sedik EMAIL logo
Published/Copyright: June 11, 2025
Journal of Basic and Clinical Physiology and Pharmacology
From the journal Journal of Basic and Clinical Physiology and Pharmacology Volume 36 Issue 4

Abstract

Heart failure (HF) represents the final manifestation of various cardiovascular diseases, emerging as a significant global health challenge that impacts over 20 million individuals worldwide. This review provides a comprehensive overview of the latest pharmacological agents developed to address HF, focusing on their effectiveness in alleviating symptoms associated with the condition. It highlights the critical necessity for a more profound understanding of the multifaceted processes and pathways that contribute to HF pathogenesis. The methodology employed in this review demonstrates encouraging outcomes from numerous pharmaceutical agents evaluated for their ability to relieve HF symptoms, showcasing their effectiveness in improving patient experiences. However, a significant gap remains in tackling the fundamental issues underlying HF. The findings emphasize the intricate nature of HF and the obstacles faced in creating therapies that extend beyond mere symptomatic management. Currently, the predominant approach to HF treatment involves targeting the underlying mechanisms of the disease and addressing related neurohumoral imbalances. Despite the growing arsenal of treatments available for HF, patient outcomes continue to be suboptimal. Therefore, this review aims to illuminate potential therapeutic targets for more effective management strategies for HF, ultimately striving to enhance patient prognosis and quality of life.

Keywords: heart failure; cardiovascular disease; pharmaceutical agents; pathogenesis; management
Corresponding author: Ahmed A. Sedik, Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, El, Buhouth St., Dokki, Giza, 12622, Egypt; and Image & Connectomics in Clinical Neuroscience, TGI, Clermont Auvergne INP, Institut Pascal, Clermont Auvergne University, Clermont Ferrand, F-63000, France, E-mail:

  1. Research ethics: The local Institutional Review Board deemed the study exempt from review.

  2. Informed consent: Informed consent was obtained from all individuals included in this study.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: Authors state no conflict of interest.

  6. Research funding: Not applicable.

  7. Data availability: Not applicable.

References

1. Sharma, N, Wani, SN, Singh, S, Zahoor, I, Behl, T, Malik, IA. Decrypting the role of angiogenesis, inflammation, and oxidative stress in pathogenesis of congestive heart failure: nanotechnology as a boon for the management of congestive heart failure. Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases. Academic Press; 2024:151–90 pp.10.1016/B978-0-443-13587-3.00009-6Search in Google Scholar

2. Ziaeian, B, Fonarow, GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368–78. https://doi.org/10.1038/nrcardio.2016.25.Search in Google Scholar PubMed PubMed Central

3. AlHabib, KF, Elasfar, AA, Alfaleh, H, Kashour, T, Hersi, A, AlBackr, H, et al.. Clinical features, management, and short- and long-term outcomes of patients with acute decompensated heart failure: phase I results of the HEARTS database. Eur J Heart Fail 2014;16:461–9. https://doi.org/10.1002/ejhf.57.Search in Google Scholar PubMed

4. Wu, DH, Senyo, SE. Scratching beneath the surface: IL4Rα blockade and the progression from myocardial ischemic injury to heart failure. Am J Physiol Heart Circ Physiol 2024;5:1177–9. https://doi.org/10.1152/ajpheart.00150.2024.Search in Google Scholar PubMed

5. Dickstein, K, Cohen-Solal, A, Filippatos, G, McMurray, JJ, Ponikowski, P, Poole-Wilson, PA, et al.. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur Heart J 2008;29:2388–442. https://doi.org/10.1093/eurheartj/ehn309.Search in Google Scholar PubMed

6. Vujičić, B, Benko, K, Petretić, A, Nemarnik, N, Spicijarić, M, Markić, D, et al.. Advanced treatment of refractory congestive heart failure by peritoneal ultrafiltration with icodextrin in patients without end-stage renal disease. Updates on Renal Replacement Therapy. IntechOpen; 2024.10.5772/intechopen.114022Search in Google Scholar

7. Lisi, M, Luisi, GA, Pastore, MC, Mandoli, GE, Benfari, G, Ilardi, F, et al.. New perspectives in the echocardiographic hemodynamics multiparametric assessment of patients with heart failure. Heart Fail Rev 2024:1–11. https://doi.org/10.1007/s10741-024-10398-7.Search in Google Scholar PubMed PubMed Central

8. Rustad, JK, Stern, TA, Hebert, KA, Musselman, DL. Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. Prim Care Companion CNS Disord 2013;15. https://doi.org/10.4088/pcc.13r01511.Search in Google Scholar PubMed PubMed Central

9. Mottram, PM, Marwick, TH. Assessment of diastolic function: what the general cardiologist needs to know. Heart 2005;91:681–95. https://doi.org/10.1136/hrt.2003.029413.Search in Google Scholar PubMed PubMed Central

10. Fukuta, H, Little, WC. The cardiac cycle and the physiologic basis of left ventricular contraction, ejection, relaxation, and filling. Heart Fail Clin 2008;4:1–11. https://doi.org/10.1016/j.hfc.2007.10.004.Search in Google Scholar PubMed PubMed Central

11. Kemp, CD, Conte, JV. The pathophysiology of heart failure. Cardiovasc Pathol 2012;21:365–71. https://doi.org/10.1016/j.carpath.2011.11.007.Search in Google Scholar PubMed

12. Inamdar, AA, Inamdar, AC. Heart failure: diagnosis, management and utilization. J Clin Med 2016;5. https://doi.org/10.3390/jcm5070062.Search in Google Scholar PubMed PubMed Central

13. D’Alto, M, Di Maio, M, Argiento, P, Romeo, E, Rea, G, Liccardo, B, et al.. Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension. Eur J Heart Fail 2024;4:817–24.10.1002/ejhf.3172Search in Google Scholar PubMed

14. Joyner, MJ, Charkoudian, N, Wallin, BG. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications. Hypertension 2010;56:10–16. https://doi.org/10.1161/hypertensionaha.109.140186.Search in Google Scholar PubMed PubMed Central

15. Brown, DA, Perry, JB, Allen, ME, Sabbah, HN, Stauffer, BL, Shaikh, SR, et al.. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol 2017;14:238–50. https://doi.org/10.1038/nrcardio.2016.203.Search in Google Scholar PubMed PubMed Central

16. Maron, BA, Leopold, JA. Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Invest Drugs 2008;9:963–9.Search in Google Scholar

17. Jackson, G, Gibbs, CR, Davies, MK, Lip, GY. ABC of heart failure. Pathophysiology. BMJ 2000;320:167–70. https://doi.org/10.1136/bmj.320.7228.167.Search in Google Scholar PubMed PubMed Central

18. Lavie, CJ, Milani, RV, Mehra, MR, Ventura, HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585–94. https://doi.org/10.1016/j.jacc.2009.02.084.Search in Google Scholar PubMed

19. Geleijnse, JM. Habitual coffee consumption and blood pressure: an epidemiological perspective. Vasc Health Risk Manag 2008;4:963–70. https://doi.org/10.2147/vhrm.s3055.Search in Google Scholar PubMed PubMed Central

20. Nagata, K, Hattori, T. Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. Nagoya J Med Sci 2011;73:91–105.Search in Google Scholar

21. Tariq, S, Aronow, WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci 2015;16:29060–8. https://doi.org/10.3390/ijms161226147.Search in Google Scholar PubMed PubMed Central

22. Saleh, DO, Mansour, DF, Mostafa, RE. Rosuvastatin and simvastatin attenuate cisplatin-induced cardiotoxicity via disruption of endoplasmic reticulum stress-mediated apoptotic death in rats: targeting ER-Chaperone GRP78 and Calpain-1 pathways. Toxicol Rep 2020;7:1178–86. https://doi.org/10.1016/j.toxrep.2020.08.026.Search in Google Scholar PubMed PubMed Central

23. Piper, S, McDonagh, T. The role of intravenous vasodilators in acute heart failure management. Eur J Heart Fail 2014;16:827–34. https://doi.org/10.1002/ejhf.123.Search in Google Scholar PubMed

24. Haji, SA, Movahed, A. Update on digoxin therapy in congestive heart failure. Am Fam Physician 2000;62:409–16.Search in Google Scholar

25. Bauman, JL, Didomenico, RJ, Galanter, WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 2006;6:77–86. https://doi.org/10.2165/00129784-200606020-00002.Search in Google Scholar PubMed

26. Naqvi, S, Ahmed, I, Siddiqi, R, Hussain, SA. Digoxin as a rescue drug in intra aortic balloon pump and inotrope dependent patients. J Ayub Med Coll Abbottabad 2010;22:8–12.Search in Google Scholar

27. Overgaard, CB, Dzavik, V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 2008;118:1047–56. https://doi.org/10.1161/circulationaha.107.728840.Search in Google Scholar

28. Cox, ZL, Calcutt, MW, Morrison, TB, Akers, WS, Davis, MB, Lenihan, DJ. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. J Cardiovasc Pharmacol Ther 2013;18:433–8. https://doi.org/10.1177/1074248413489773.Search in Google Scholar PubMed

29. Michael, FG. Diuretic management in heart failure. Congest Heart Fail 2010;16(1 Suppl):S68–72. https://doi.org/10.1111/j.1751-7133.2010.00172.x.Search in Google Scholar PubMed

30. Pellicori, P, Kaur, K, Clark, AL. Fluid management in patients with chronic heart failure. Card Fail Rev 2015;1:90–5. https://doi.org/10.15420/cfr.2015.1.2.90.Search in Google Scholar PubMed PubMed Central

31. Felker, GM, Ellison, DH, Mullens, W, Cox, ZL, Testani, JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. JACC 2020;75:1178–95. https://doi.org/10.1016/j.cardfail.2014.06.353.Search in Google Scholar PubMed

32. Shchekochikhin, D, Al Ammary, F, Lindenfeld, JA, Schrier, R. Role of diuretics and ultrafiltration in congestive heart failure. Pharmaceuticals 2013;6:851–66. https://doi.org/10.3390/ph6070851.Search in Google Scholar PubMed PubMed Central

33. Ravnan, SL, Ravnan, MC, Deedwania, PC. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail 2002;8:80–5. https://doi.org/10.1111/j.1527-5299.2002.0758.x.Search in Google Scholar PubMed

34. Massari, F, Mastropasqua, F, Iacoviello, M, Nuzzolese, V, Torres, D, Parrinello, G. The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde? Am J Emerg Med 2012;30:517 e515–510. https://doi.org/10.1016/j.ajem.2011.01.023.Search in Google Scholar PubMed

35. Pazos-Lopez, P, Peteiro-Vazquez, J, Carcia-Campos, A, Garcia-Bueno, L, de Torres, JP, Castro-Beiras, A. The causes, consequences, and treatment of left or right heart failure. Vasc Health Risk Manag 2011;7:237–54. https://doi.org/10.2147/vhrm.s10669.Search in Google Scholar PubMed PubMed Central

36. Ramani, GV, Uber, PA, Mehra, MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 2010;85:180–95. https://doi.org/10.4065/mcp.2009.0494.Search in Google Scholar PubMed PubMed Central

37. Okwuosa, IS, Princewill, O, Nwabueze, C, Mathews, L, Hsu, S, Gilotra, NA, et al.. The ABCs of managing systolic heart failure: past, present, and future. Cleve Clin J Med 2016;83:753–65. https://doi.org/10.3949/ccjm.83a.16006.Search in Google Scholar PubMed

38. Zhang, X, Shen, C, Zhai, S, Liu, Y, Yue, WW, Han, L. A meta-analysis of the effects of beta-adrenergic blockers in chronic heart failure. Exp Ther Med 2016;12:2489–96. https://doi.org/10.3892/etm.2016.3657.Search in Google Scholar PubMed PubMed Central

39. Chamsi-Pasha, MA, Shao, Z, Tang, WH. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep 2014;11:58–63. https://doi.org/10.1007/s11897-013-0178-0.Search in Google Scholar PubMed PubMed Central

40. Unger, T, Li, J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 2004;5(1 Suppl):S7–10. https://doi.org/10.3317/jraas.2004.024.Search in Google Scholar PubMed

41. Shibata, MC, Tsuyuki, RT, Wiebe, N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract 2008;62:1397–402. https://doi.org/10.1111/j.1742-1241.2008.01806.x.Search in Google Scholar PubMed

42. Owens, AT, Brozena, SC, Jessup, M. New management strategies in heart failure. Circ Res 2016;118:480–95. https://doi.org/10.1161/circresaha.115.306567.Search in Google Scholar

43. Fisher, ND, Jan Danser, AH, Nussberger, J, Dole, WP, Hollenberg, NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117:3199–205. https://doi.org/10.1161/circulationaha.108.767202.Search in Google Scholar

44. McMurray, JJ, Krum, H, Abraham, WT, Dickstein, K, Kober, LV, Desai, AS, et al.. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016;374:1521–32. https://doi.org/10.1056/nejmoa1514859.Search in Google Scholar PubMed

45. Manolis, AA, Manolis, TA, Manolis, AS. Neurohumoral activation in heart failure. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms242015472.Search in Google Scholar PubMed PubMed Central

46. Song, W, Wang, H, Wu, Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015;569:1–6. https://doi.org/10.1016/j.gene.2015.06.029.Search in Google Scholar PubMed PubMed Central

47. Jhund, PS, McMurray, JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart 2016;102:1342–7. https://doi.org/10.1136/heartjnl-2014-306775.Search in Google Scholar PubMed PubMed Central

48. McMurray, JJ, Packer, M, Desai, AS, Gong, J, Lefkowitz, MP, Rizkala, AR, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/nejmoa1409077.Search in Google Scholar PubMed

49. Santos, RA, Ferreira, AJ, Verano-Braga, T, Bader, M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013;216:R1–17. https://doi.org/10.1530/joe-12-0341.Search in Google Scholar PubMed

50. Burrell, LM, Risvanis, J, Kubota, E, Dean, RG, MacDonald, PS, Lu, S, et al.. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005;26:369–75. https://doi.org/10.1093/eurheartj/ehi114.Search in Google Scholar PubMed

51. Crackower, MA, Sarao, R, Oudit, GY, Yagil, C, Kozieradzki, I, Scanga, SE, et al.. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822–8. https://doi.org/10.1038/nature00786.Search in Google Scholar PubMed

52. Kittana, N. Angiotensin converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment. Fundam Clin Pharmacol 2017;1:14–25. https://doi.org/10.1111/fcp.12318.Search in Google Scholar PubMed

53. Wang, W, Patel, VB, Parajuli, N, Fan, D, Basu, R, Wang, Z, et al.. Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med 2014;92:847–58. https://doi.org/10.1007/s00109-014-1149-y.Search in Google Scholar PubMed

54. Tse, S, Mazzola, N. Ivabradine (corlanor) for heart failure: the first selective and specific I f inhibitor. P T 2015;40:810–14.Search in Google Scholar

55. Bouabdallaoui, N, O’Meara, E, Bernier, V, Komajda, M, Swedberg, K, Tavazzi, L, et al.. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Fail 2019;6:1199–207. https://doi.org/10.1002/ehf2.12513.Search in Google Scholar PubMed PubMed Central

56. Yaniv, Y, Maltsev, VA, Ziman, BD, Spurgeon, HA, Lakatta, EG. The “funny” current (I(f)) inhibition by ivabradine at membrane potentials encompassing spontaneous depolarization in pacemaker cells. Molecules 2012;17:8241–54. https://doi.org/10.3390/molecules17078241.Search in Google Scholar PubMed PubMed Central

57. Thorup, L, Simonsen, U, Grimm, D, Hedegaard, ER. Ivabradine: current and future treatment of heart failure. Basic Clin Pharmacol Toxicol 2017;121:89–97. https://doi.org/10.1111/bcpt.12784.Search in Google Scholar PubMed

58. Yang, J, Lv, T, Zhou, J, Lin, H, Zhao, B, Lou, H, et al.. The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis. Front Cardiovasc Med 2023;10. https://doi.org/10.3389/fcvm.2023.1149351.Search in Google Scholar PubMed PubMed Central

59. Lin, YS, Jan, JY, Chang, JJ, Lin, MS, Yang, TY, Wang, PC, et al.. Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation. ESC Heart Fail 2022;9:2548–57. https://doi.org/10.1002/ehf2.13966.Search in Google Scholar PubMed PubMed Central

60. Fala, L. Corlanor (ivabradine), first HCN channel blocker, FDA approved for the treatment of patients with heart failure. Am Health Drug Benefit 2016;9:56–9.Search in Google Scholar

61. Chaudhary, KR, El-Sikhry, H, Seubert, JM. Mitochondria and the aging heart. J Geriatr Cardiol 2011;8:159–67. https://doi.org/10.3724/sp.j.1263.2011.00159.Search in Google Scholar PubMed PubMed Central

62. Nguyen, BY, Ruiz-Velasco, A, Bui, T, Collins, L, Wang, X, Liu, W. Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials. Br J Pharmacol 2019;176:4302–18. https://doi.org/10.1111/bph.14431.Search in Google Scholar PubMed PubMed Central

63. Bayeva, M, Gheorghiade, M, Ardehali, H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2013;61:599–610. https://doi.org/10.1016/j.jacc.2012.08.1021.Search in Google Scholar PubMed PubMed Central

64. Dutta, D, Calvani, R, Bernabei, R, Leeuwenburgh, C, Marzetti, E. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circ Res 2012;110:1125–38. https://doi.org/10.1161/circresaha.111.246108.Search in Google Scholar

65. Fillmore, N, Mori, J, Lopaschuk, GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 2014;171:2080–90. https://doi.org/10.1111/bph.12475.Search in Google Scholar PubMed PubMed Central

66. Actis Dato, V, Lange, S, Cho, Y. Metabolic flexibility of the heart: the role of fatty acid metabolism in health. Heart Fail Cardiometab Dis 2024;25. https://doi.org/10.3390/ijms25021211.Search in Google Scholar PubMed PubMed Central

67. Sheeran, FL, Pepe, S. Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate. Biochim Biophys Acta 2006;1757:543–52. https://doi.org/10.1016/j.bbabio.2006.03.008.Search in Google Scholar PubMed

68. Patergnani, S, Bouhamida, E, Leo, S, Pinton, P, Rimessi, A. Mitochondrial oxidative stress and “mito-inflammation”: actors in the diseases. Biomedicines 2021;9. https://doi.org/10.3390/biomedicines9020216.Search in Google Scholar PubMed PubMed Central

69. Gallo, G, Rubattu, S, Volpe, M. Mitochondrial dysfunction in heart failure: from pathophysiological mechanisms to therapeutic opportunities. Int J Mol Sci 2024;25. https://doi.org/10.3390/ijms25052667.Search in Google Scholar PubMed PubMed Central

70. Walters, AM, Porter, JGA, Brookes, PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 2012;111:1222–36. https://doi.org/10.1161/circresaha.112.265660.Search in Google Scholar

71. Ramirez-Sanchez, I, Taub, PR, Ciaraldi, TP, Nogueira, L, Coe, T, Perkins, G, et al.. (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. Int J Cardiol 2013;168:3982–90. https://doi.org/10.1016/j.ijcard.2013.06.089.Search in Google Scholar PubMed PubMed Central

72. Shaki, F, Shayeste, Y, Karami, M, Akbari, E, Rezaei, M, Ataee, R. The effect of epicatechin on oxidative stress and mitochondrial damage induced by homocycteine using isolated rat hippocampus mitochondria. Res Pharm Sci 2017;12:119–27. https://doi.org/10.4103/1735-5362.202450.Search in Google Scholar PubMed PubMed Central

73. Sung, MM, Dyck, JR. Therapeutic potential of resveratrol in heart failure. Ann N Y Acad Sci 2015;1348:32–45. https://doi.org/10.1111/nyas.12839.Search in Google Scholar PubMed

74. Sedik, AA, Hassan, A, Saleh, DO. Neuromodulatory role of L-arginine: nitric oxide precursor against thioacetamide-induced-hepatic encephalopathy in rats via downregulation of NF-κB-mediated apoptosis. Environ Sci Pollut Control Ser 2023;30:84791–804. https://doi.org/10.1007/s11356-023-28184-7.Search in Google Scholar PubMed PubMed Central

75. Walters, AM, Porter, GAJr., Brookes, PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 2012;111:1222–36. https://doi.org/10.1161/circresaha.112.265660.Search in Google Scholar

76. Abozguia, K, Elliott, P, McKenna, W, Phan, TT, Nallur-Shivu, G, Ahmed, I, et al.. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010;122:1562–9. https://doi.org/10.1161/circulationaha.109.934059.Search in Google Scholar

77. Bhashyam, S, Fields, AV, Patterson, B, Testani, JM, Chen, L, Shen, YT, et al.. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010;3:512–21. https://doi.org/10.1161/circheartfailure.109.900282.Search in Google Scholar

78. A, SA. Modulation activity of vildagliptin on hepatic complications and lipoprotein abnormalities associated with insulin resistance in rats. Egypt J Chem 2022;65:541–7.Search in Google Scholar

79. Margulies, KB, Anstrom, KJ, Hernandez, AF, Redfield, MM, Shah, MR, Braunwald, E, et al.. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail 2014;7:673–9. https://doi.org/10.1161/circheartfailure.114.000346.Search in Google Scholar

80. Alhumaidha, KA, Saleh, DO, Fattah, MAAE, El-Eraky, WI, Moawad, H. Cardiorenal protective effect of taurine against cyclophosphamide-induced toxicity in albino rats. Can J Physiol Pharmacol 2016;94:131–9. https://doi.org/10.1139/cjpp-2015-0138.Search in Google Scholar PubMed

81. Kiyuna, LA, Albuquerque, RP, Chen, C-H, Mochly-Rosen, D, Ferreira, JCB. Targeting mitochondrial dysfunction and oxidative stress in heart failure: challenges and opportunities. Free Radic Biol Med 2018;129:155–68. https://doi.org/10.1016/j.freeradbiomed.2018.09.019.Search in Google Scholar PubMed PubMed Central

82. Brown, DA, Jew, KN, Sparagna, GC, Musch, TI, Moore, RL. Exercise training preserves coronary flow and reduces infarct size after ischemia-reperfusion in rat heart. J Appl Physiol (1985) 2003;95:2510–18. https://doi.org/10.1152/japplphysiol.00487.2003.Search in Google Scholar PubMed

83. Brown, DA, Moore, RL. Perspectives in innate and acquired cardioprotection: cardioprotection acquired through exercise. J Appl Physiol (1985) 2007;103:1894–9. https://doi.org/10.1152/japplphysiol.00464.2007.Search in Google Scholar PubMed

84. Apostolova, N, Victor, VM. Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid Redox Signal 2015;22:686–729. https://doi.org/10.1089/ars.2014.5952.Search in Google Scholar PubMed PubMed Central

85. Marshall, KD, Muller, BN, Krenz, M, Hanft, LM, McDonald, KS, Dellsperger, KC, et al.. Heart failure with preserved ejection fraction: chronic low-intensity interval exercise training preserves myocardial O2 balance and diastolic function. J Appl Physiol (1985) 2013;114:131–47. https://doi.org/10.1152/japplphysiol.01059.2012.Search in Google Scholar PubMed PubMed Central

86. Tsui, KH, Li, CJ. Mitoquinone shifts energy metabolism to reduce ROS-induced oxeiptosis in female granulosa cells and mouse oocytes. Aging 2023;15:246–60. https://doi.org/10.18632/aging.204475.Search in Google Scholar PubMed PubMed Central

87. Suliman, HB, Piantadosi, CA. Mitochondrial quality control as a therapeutic target. Pharmacol Rev 2016;68:20–48. https://doi.org/10.1124/pr.115.011502.Search in Google Scholar PubMed PubMed Central

88. Roser, KS, Brookes, PS, Wojtovich, AP, Olson, LP, Shojaie, J, Parton, RL, et al.. Mitochondrial biotransformation of omega-(phenoxy)alkanoic acids, 3-(phenoxy)acrylic acids, and omega-(1-methyl-1H-imidazol-2-ylthio)alkanoic acids: a prodrug strategy for targeting cytoprotective antioxidants to mitochondria. Bioorg Med Chem 2010;18:1441–8. https://doi.org/10.1016/j.bmc.2010.01.019.Search in Google Scholar PubMed PubMed Central

89. Robichaux, DJ, Harata, M, Murphy, E, Karch, J. Mitochondrial permeability transition pore-dependent necrosis. J Mol Cell Cardiol 2023;174:47–55. https://doi.org/10.1016/j.yjmcc.2022.11.003.Search in Google Scholar PubMed PubMed Central

90. Hefler, J, Marfil-Garza, BA, Campbell, S, Freed, DH, Shapiro, AMJ. Preclinical systematic review & meta-analysis of cyclosporine for the treatment of myocardial ischemia-reperfusion injury. Ann Transl Med 2022;10:954. https://doi.org/10.21037/atm-22-618.Search in Google Scholar PubMed PubMed Central

91. Guven, C, Taskin, E, Aydın, Ö, Kaya, ST, Sevgiler, Y. Diazoxide attenuates DOX-induced cardiotoxicity in cultured rat myocytes. Biotech Histochem 2024:1–12. https://doi.org/10.1080/10520295.2024.2324368.Search in Google Scholar PubMed

92. Osorio-Llanes, E, Castellar-L, J, Rosales, W, Montoya, Y, Bustamante, J, Zalaquett, R, et al.. Novel strategies to improve the cardioprotective effects of cardioplegia. Curr Cardiol Rev 2024;20:39–52. https://doi.org/10.2174/011573403x263956231129064455.Search in Google Scholar PubMed PubMed Central

93. Sato, T, Li, Y, Saito, T, Nakaya, H. Minoxidil opens mitochondrial K(ATP) channels and confers cardioprotection. Br J Pharmacol 2004;141:360–6. https://doi.org/10.1038/sj.bjp.0705613.Search in Google Scholar PubMed PubMed Central

94. Steffen, RJ, Blackstone, EH, Smedira, NG, Soltesz, EG, Hoercher, KJ, Thuita, L, et al.. Optimal timing of heart transplant after HeartMate II left ventricular assist device implantation. Ann Thorac Surg 2017;4:1569–76. https://doi.org/10.1016/j.athoracsur.2017.03.066.Search in Google Scholar PubMed

95. Bounader, K, Flécher, E. End-stage heart failure: the future of heart transplant and artificial heart. Presse Med 2024;53:104191. https://doi.org/10.1016/j.lpm.2023.104191.Search in Google Scholar PubMed

96. Heidary, RA, Mahdavi-Mazdeh, M. Regenerative medicine in organ and tissue transplantation: shortly and practically achievable? Int J Organ Transplant Med 2015;6:93–8.Search in Google Scholar

97. Wang, J, Deng, G, Wang, S, Li, S, Song, P, Lin, K, et al.. Enhancing regenerative medicine: the crucial role of stem cell therapy. Front Neurosci 2024;18:1269577. https://doi.org/10.3389/fnins.2024.1269577.Search in Google Scholar PubMed PubMed Central

98. Pistelli, L, Parisi, F, Correale, M, Cocuzza, F, Campanella, F, de Ferrari, T, et al.. Gliflozins: from antidiabetic drugs to cornerstone in heart failure therapy-A boost to their utilization and multidisciplinary approach in the management of heart failure. J Clin Med 2023;12. https://doi.org/10.3390/jcm12010379.Search in Google Scholar PubMed PubMed Central

99. Song, R, Zhang, L. MicroRNAs and therapeutic potentials in acute and chronic cardiac disease. Drug Discov Today 2024;29:104179. https://doi.org/10.1016/j.drudis.2024.104179.Search in Google Scholar PubMed

100. Szentandrássy, N, Magyar, Z, Hevesi, J, Bányász, T, Nánási, PP, Almássy, J. Therapeutic approaches of ryanodine receptor-associated heart diseases. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23084435.Search in Google Scholar PubMed PubMed Central

101. Campbell, H, Aguilar-Sanchez, Y, Quick, AP, Dobrev, D, Wehrens, XHT. SPEG: a key regulator of cardiac calcium homeostasis. Cardiovasc Res 2021;117:2175–85. https://doi.org/10.1093/cvr/cvaa290.Search in Google Scholar PubMed PubMed Central

102. Gabisonia, K, Recchia, FA. Gene therapy for heart failure: new perspectives. Curr Heart Fail Rep 2018;15:340–9. https://doi.org/10.1007/s11897-018-0410-z.Search in Google Scholar PubMed PubMed Central

Received: 2024-12-24
Accepted: 2025-05-27
Published Online: 2025-06-11

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving horizon
  4. Reviews
  5. Insight into novel therapeutic targets in heart failure: a comprehensive review
  6. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials
  7. Lymph node ultrasound in lymphoproliferative disorders: clinical characteristics and applications
  8. Original Article
  9. A critical comparison of pharmacovigilance reporting forms in six countries with the WHO-UMC recommendations (form of the form)
https://doi.org/10.1515/jbcpp-2024-0234
Keywords for this article
heart failure; cardiovascular disease; pharmaceutical agents; pathogenesis; management

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving horizon
  4. Reviews
  5. Insight into novel therapeutic targets in heart failure: a comprehensive review
  6. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials
  7. Lymph node ultrasound in lymphoproliferative disorders: clinical characteristics and applications
  8. Original Article
  9. A critical comparison of pharmacovigilance reporting forms in six countries with the WHO-UMC recommendations (form of the form)
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 8.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2024-0234/html
Scroll to top button